Long-term follow-up of people treated with NTLA-2001 for transthyretin amyloidosis
Follows adults who received NTLA-2001 earlier, to observe its long-term effects.
Plain-language title generated from the registry record
Registry title: Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
Key facts
- Where
- Umea, SwedenSee the site
- Phase
- Phase 2/3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who already received NTLA-2001 (a full or partial dose) in an earlier Intellia-sponsored study. It follows them over time to see the long-term effects.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Earlier treatment
- Must have received a full or partial dose of NTLA-2001 in an earlier Intellia-sponsored clinical study, and finished or stopped that study.
Read by machine on 9 November 2026.
Where in Sweden
- Region VaesterbottenUmea, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Intellia Therapeutics
- Trial code
- NCT05697861EU 2023-507385-11-00
- Record updated
- 3 August 2026
- Original description
This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.Read full original descriptionShow less
Long-Term Follow-Up of Subjects Treated With NTLA-2001
This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.
Inclusion: A subject has completed or discontinued from an Intellia-sponsored clinical study in which a complete or partial dose of NTLA-2001 was received; A subject has provided informed consent for the LTFU study.
Exclusion: None.